Infants with Down Syndrome and Congenital Heart Disease Have Altered Peri-operative Immune Responses
Overview
Authors
Affiliations
Background: Infants with Down syndrome (DS) have an altered immune response. We aimed to characterise the inflammatory response in infants with DS and congenital heart disease (CHD) peri-operatively in comparison to infants with CHD and a normal chromosomal complement, and to healthy infants pre-operatively.
Methods: Infants with DS/CHD, infants without DS but with CHD (CHD only) and healthy infants were prospectively recruited and serial serum cytokines evaluated peri-operatively using multiplex ELISA: tumour necrosis factor (TNF)-α and TNF-β; interferon (IFN)-γ, interleukin (IL)-1α, IL-2, IL-6, IL-8, IL-18, IL-1β, IL-10, and IL-1ra; vascular endothelial growth factor (VEGF); granulocyte macrophage colony-stimulating factor (GM-CSF); and erythropoietin (EPO).
Results: Ninety-four infants were recruited including age-matched controls (n = 10), DS/CHD (n = 55), and CHD only (n = 29). Children with DS/CHD had significantly lower concentrations of several cytokines (IL-10, IL-6, IL-8, IL-1β, VEGF) in the pre- and post-operatively vs CHD only and controls. EPO and GM-CSF were significantly higher in DS/CHD (p value <0.05).
Conclusions: Children with DS/CHD had significantly lower concentrations of several cytokines compared to controls or children with CHD only. EPO and GM-CSF were significantly higher in children with DS/CHD. The assessment of the immune response may be suitable for the predictable clinical outcomes in these children.
Impact: This study demonstrated that children with Down syndrome (DS) and congenital heart disease (CHD) have significant alterations in pro-inflammatory and anti-inflammatory immune responses peri-operatively. These changes may contribute to adverse clinical outcomes, including sepsis, chylothorax, and autoimmunity. They may impact the pathogenesis and outcome post-operatively and long term in this population. Children with DS and CHD have significantly lower cytokine concentrations, increased EPO and GM-CSF, and decreased VEGF pre- and post-operatively. Assessing their inflammatory state peri-operatively may facilitate the development of a predictive model that can inform tailored management of these infants using novel therapies including immunomodulation.
Ishizu K, Araki K, Kagisaki K, Ozawa H Surg Case Rep. 2025; 11(1).
PMID: 39995518 PMC: 11850031. DOI: 10.70352/scrj.cr.24-0112.
In reply: Additional Insights into the REPLICA-PH study.
Walian A, Magoon R, Shri I, Kashav R Braz J Cardiovasc Surg. 2024; 39(3):e20230290.
PMID: 38630607 PMC: 11022419. DOI: 10.21470/1678-9741-2023-0290.
Epigenomic signature of major congenital heart defects in newborns with Down syndrome.
Mouat J, Li S, Myint S, Laufer B, Lupo P, Schraw J Hum Genomics. 2023; 17(1):92.
PMID: 37803336 PMC: 10559462. DOI: 10.1186/s40246-023-00540-1.
Epigenomic signature of major congenital heart defects in newborns with Down syndrome.
Mouat J, Li S, Myint S, Laufer B, Lupo P, Schraw J medRxiv. 2023; .
PMID: 37205408 PMC: 10187438. DOI: 10.1101/2023.05.02.23289417.